U.S. Anorexiants Market, By Drug Class (Catecholamines Anorexiants, Serotonin Anorexiants), Drug Type (Generics, Branded), Applications (Weight Loss, Obesity, Attention Deficit Hyperactivity Disorder (ADHD), Dravet Syndrome), Prescription Mode (Prescription, OTC), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
U.S. Anorexiants Market Analysis and Size
Obesity can be well-treated with anorexiants. According to the World Health Organization report, about 650 million people and 41 million children under the age of 5 years were obese worldwide in 2017. Many of the drugs have been licensed by the FDA for the treatment of obesity, the anorexiants market is projected to rise in the upcoming years. The increasing presence of major market players, a huge target population with disposable income in the U.S. is expected to increase the market growth during the forecast period.
Data Bridge Market Research analyses a growth rate in the U.S. anorexiants market in the forecast period 2022-2030. The expected CAGR of the U.S. anorexiants market tends to be around 4% in the mentioned forecast period. The market value is USD 217.8 million in 2022, and it would grow up to USD 298.07 million by 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
U.S. Anorexiants Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2030
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Class (Catecholamines Anorexiants, Serotonin Anorexiants), Drug Type (Generics, Branded), Applications (Weight Loss, Obesity, Attention Deficit Hyperactivity Disorder (ADHD), Dravet Syndrome), Prescription Mode (Prescription, OTC), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Sanofi (France), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), Johnson & Johnson Private Limited (U.S.), Aurobindo Pharma (India), Cipla Inc. (U.S.), Lannett (U.S.), Bausch Health Companies Inc. (Canada), Sun Pharmaceutical Industries Ltd. (India), Novo Nordisk A/S (Denmark), Currax Pharmaceuticals LLC (U.S.), Eisai Co., Ltd. (Japan), Merck & Co., Inc. (U.S.), Par Pharmaceutical (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Anorexiants, often called appetite suppressants, are a kind of medication that is used to treat obesity. This medicine decreases food consumption by acting on the brain to hinder appetite. Anorexiants are CNS stimulants that helps to minimize appetite and are accessible as immediate and extended-release tablets. These are prescription medications which should be used in conjunction with a low-calorie diet and regular exercise.
U.S. Anorexiants Market Dynamics
Drivers
- Increasing Occurrence of Obesity
The growing incidence of obesity globally will boost the industry growth. Obesity is a type of condition in which the body fat levels have gathered to the point where they are causing health problems. When people intake more calories, this condition occurs. Obesity increases the risk of chronic diseases such colon cancer, type 2 diabetes, breast cancer, endometrial cancer, cardiovascular disease, and musculoskeletal issues. According to the World Health Organization records, obesity affected about 650 million people and 340 million children and adolescents worldwide in 2016. Similarly, according to the Organization for Economic Co-operation and Development report in 2020, the U.S. is projected to spend the highest Health Expenditure on Obesity and Related Conditions globally during 2020-2050. This boosts the market growth.
Opportunities
- Increase in Strategic Developments
Some of the major market players are employing numerous strategies such as increased investments in R&D and mergers and acquisitions. For instance, Currax Pharmaceuticals LLC, acquired Nalpropion Pharmaceuticals in September 2019 to focus on the treatment of weight loss. With the acquisition deal, Currax has owned the world-wide rights to Contrave, the number one prescription weight-loss brand medication in the U.S. and Europe. This increases the market growth.
- Rising Demand of Oral Route of Administration
Oral anorexiants dominated the market in past few years, and it is anticipated to do so during the forecast period. The increasing demand for these products can be because of the increased inclination of the patients due to their non-invasive treatment. Similarly, their easier administration without needing trained healthcare professionals increased the patient and physician adoption rate. Additionally, increasing availability of products in tablets and capsules, along with the increased awareness by major market players are anticipated to lead to the growth of the segment.
Restraints/Challenges
- Lack of Skilled Professionals
Dearth of skilled healthcare professionals who are unaware of the appropriate use of anorexiants could reduce the growth of the U.S. anorexiants market during the forecast period 2023-2030. Otherwise use of these stimulants could affect the patient badly and lead to the hindrance of the market.
- Side Effects Associated with Anorexiants
There are various side effects that are linked with the anorexiants such as tachycardia, headache, diarrhea, myalgia, insomnia, vomiting, nausea and others will act as a limit and further hinder the growth rate of market
This U.S. anorexiants market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the U.S. anorexiants market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
U.S. Anorexiants Market Scope
The U.S. anorexiants market is segmented on the basis of drug class, indication, route of administration, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Catecholamines Anorexiants
- Serotonin Anorexiants
Indication
- ADHD
- Dravet Syndrome
- Lennox-Gastaut Syndrome
- Obesity
- Weight Loss
- Others
Route of Administration
- Oral
- Subcutaneous
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Competitive Landscape and U.S. Anorexiants Market Share Analysis
The U.S. anorexiants market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, U.S. presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to U.S. anorexiants market.
Key players operating in the U.S. anorexiants market include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- Novartis AG (Switzerland)
- Merck & Co., Inc. (U.S.)
- Johnson & Johnson Private Limited (U.S.)
- Aurobindo Pharma (India)
- Cipla Inc. (U.S.)
- Lannett (U.S.)
- Bausch Health Companies Inc. (Canada)
- Sun Pharmaceutical Industries Ltd. (India)
- Novo Nordisk A/S (Denmark)
- Currax Pharmaceuticals LLC (U.S.)
- Eisai Co., Ltd. (Japan)
- Merck & Co., Inc. (U.S.)
- Par Pharmaceutical (U.S.)
SKU-